Adverum Stock Today


USD 0.64  0.02  3.03%   

Market Performance
0 of 100
Odds Of Distress
Less than 27
Adverum Biotechnologies is selling for 0.64 as of the 7th of December 2022. This is a -3.03% down since the beginning of the trading day. The stock's lowest day price was 0.64. Adverum Biotechnologies has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Adverum Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of November 2022 and ending today, the 7th of December 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
31st of July 2014
Health Care
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 99.73 M outstanding shares of which 2.43 M shares are presently shorted by private and institutional investors with about 6.76 trading days to cover. More on Adverum Biotechnologies

Moving together with Adverum Biotechnologies

+0.79CDNACaredx Inc Buyout TrendPairCorr
+0.72CSBRChampions Oncology Earnings Call This WeekPairCorr

Moving against Adverum Biotechnologies

-0.9GILDGilead Sciences Sell-off TrendPairCorr
-0.88BMYBristol-Myers Squibb Aggressive PushPairCorr
-0.88LLYEli Lilly And Sell-off TrendPairCorr
-0.85ABBVAbbVie Inc Sell-off TrendPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Adverum Biotechnologies Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Adverum Biotechnologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Adverum Biotechnologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Adverum Biotechnologies generated a negative expected return over the last 90 days
Adverum Biotechnologies has some characteristics of a very speculative penny stock
Adverum Biotechnologies has high historical volatility and very poor performance
The company reported the previous year's revenue of 7.5 M. Net Loss for the year was (145.54 M) with loss before overhead, payroll, taxes, and interest of (81.68 M).
Adverum Biotechnologies currently holds about 235.84 M in cash with (107.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are held by institutions such as insurance companies
CEO, DirectorPaul Cleveland
Fama & French Classification
Average Analyst Recommendation
Analysts covering Adverum Biotechnologies report their recommendations after researching Adverum Biotechnologies' financial statements, talking to executives and customers, or listening in on Adverum Biotechnologies' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Adverum Biotechnologies. The Adverum consensus assessment is calculated by taking the average forecast from all of the analysts covering Adverum Biotechnologies.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Adverum Biotechnologies based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Adverum Biotechnologies financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted105.8 M98 M
Significantly Up
Slightly volatile
Weighted Average Shares105.8 M98 M
Significantly Up
Slightly volatile
Current Liabilities23 M21.3 M
Significantly Up
Slightly volatile
Total Liabilities133.3 M123.5 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Total Debt109.1 M101.1 M
Significantly Up
Slightly volatile
Asset Turnover0.01920.0187
Fairly Up
Slightly volatile
Current Assets342.2 M317.1 M
Significantly Up
Slightly volatile
Total Assets474.4 M439.7 M
Significantly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Adverum Biotechnologies' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Adverum Biotechnologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Adverum Biotechnologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adverum Biotechnologies' financial leverage. It provides some insight into what part of Adverum Biotechnologies' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Adverum Biotechnologies' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Adverum Biotechnologies deploys its capital and how much of that capital is borrowed.
Adverum Biotechnologies cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 105.48 M in liabilities with Debt to Equity (D/E) ratio of 0.43, which is about average as compared to similar companies. Adverum Biotechnologies has a current ratio of 7.87, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Adverum Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Adverum Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adverum Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adverum to invest in growth at high rates of return. When we think about Adverum Biotechnologies' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(110.67 Million)
Adverum Biotechnologies (ADVM) is traded on NASDAQ Exchange in USA and employs 188 people. Adverum Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adverum Biotechnologies's market, we take the total number of its shares issued and multiply it by Adverum Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Adverum Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 99.73 M outstanding shares of which 2.43 M shares are presently shorted by private and institutional investors with about 6.76 trading days to cover. Adverum Biotechnologies currently holds about 235.84 M in cash with (107.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Adverum Biotechnologies Probability Of Bankruptcy
Adverum Biotechnologies retains a total of 99.73 Million outstanding shares. Over half of Adverum Biotechnologies outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Adverum Biotechnologies. Please watch out for any change in the institutional holdings of Adverum Biotechnologies as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Adverum Ownership Details

Adverum Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Adverum Biotechnologies jumping above the current price in 90 days from now is under 95%. The Adverum Biotechnologies probability density function shows the probability of Adverum Biotechnologies stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.032. This suggests Adverum Biotechnologies market returns are highly reactive to returns on the market. As the market goes up or down, Adverum Biotechnologies is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Adverum Biotechnologies is significantly underperforming NYSE Composite.
  Odds Below 0.64HorizonTargetOdds Above 0.64
5.45%90 days
Based on a normal probability distribution, the odds of Adverum Biotechnologies to move above the current price in 90 days from now is under 95 (This Adverum Biotechnologies probability density function shows the probability of Adverum Stock to fall within a particular range of prices over 90 days) .

Adverum Biotechnologies Historical Income Statement

Adverum Biotechnologies Income Statement is one of the three primary financial statements used for reporting Adverum's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Adverum Biotechnologies revenue and expense. Adverum Biotechnologies Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Adverum Biotechnologies Research and Development Expense is relatively stable at the moment as compared to the past year. The company's current value of Research and Development Expense is estimated at 96.22 Million. Selling General and Administrative Expense is expected to hike to about 69.5 M this year, although the value of Earning Before Interest and Taxes EBIT will most likely fall to (149.4 M). View More Fundamentals

Adverum Stock Against Markets

Picking the right benchmark for Adverum Biotechnologies stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Adverum Biotechnologies stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Adverum Biotechnologies is critical whether you are bullish or bearish towards Adverum Biotechnologies at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Adverum Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Adverum Biotechnologies Corporate Directors

Adverum Biotechnologies corporate directors refer to members of an Adverum Biotechnologies board of directors. The board of directors generally takes responsibility for the Adverum Biotechnologies' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Adverum Biotechnologies' board members must vote for the resolution. The Adverum Biotechnologies board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
James Scopa - DirectorProfile
Lawrence Kam - DirectorProfile
Patrick Machado - Independent DirectorProfile
Thomas Woiwode - DirectorProfile

Invested in Adverum Biotechnologies?

The danger of trading Adverum Biotechnologies is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adverum Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adverum Biotechnologies. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adverum Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for analysis

When running Adverum Biotechnologies price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
65.8 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adverum Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.